While multiple plasma biomarkers changed in preclinical AD, p-tau231 and p-tau217 showed superior sensitivity to early amyloid accumulation. The molecular basis for this differential performance compared to p-tau181, GFAP, or NfL is not mechanistically explained. Gap type: unexplained_observation Source paper: Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer's disease. (2022, Nature medicine, PMID:35953717)
0
investigations
0
debates
pubmed:35953717
source
Scores
Importance
0.850
Tractability
0.800
Priority
0.820
Market Price
0.500